News
Novo Nordisk drops Wegovy collaboration with Hims & Hers, alleges unsafe tactics
Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing tactics and illegal compounding, risking patient safety.Novo Nordisk began collaborating with telehealth companies in late April,
Daily Voice on MSN1d
Plainsboro-Based Wegovy Provider Ends Hims & Hers Deal Over Knockoff Weight-Loss Drug SalesNovo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
TUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to ...
Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback